Subject:
- Active Substance: Voretigene neparvovec
- Name: Luxturna®
- Therapeutic area: Retinal dystrophy
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Start: 01.04.2022
- Final decision by G-BA: 15.09.2022
Final decision:
- Hint for a considerable additional benefit